Careers
Press Releases
Newsroom
Investor Relations
Privacy Policy
Site Directory
Terms & Conditions
| The world’s leader in diagnostic |
|
|
|
|
|
|
Learn about Quest Diagnostics' testing services for ovarian and cervical cancers — including the new FDA-cleared OVA1™ test.
March is colorectal cancer screening month. Do you have the guts to get screened? Learn more here >
Find out how adopting Care360 today can prepare your practice for tomorrow. Our modular system enables you to take a step-wise approach to technology adoption. For a limited time Care360 EHR, and the ePrescribing module of Care360 Labs & Meds, are available in a 90 day Free trial.
HEALTH TESTING YOU CHOOSE™ - Get an assessment of your personal health based on laboratory tests and diagnostic test kits that you can order directly online. You can have the results of the tests that you register for made available to you via the web or via other electronically retrievable means, or have printed reports mailed to you.
Register now for the Case-oriented Symposium on Bleeding and Thrombosis. Topics include pharmacogenetics to optimize anticoagulant therapy, platelet disorders, aspirin resistance, von Willebrand Disease, Lupus Anticoagulants, women's health issues, and pediatric hemostasis. March 18-19, 2010. Continuing education credit.
OVA1 Blood Test Now Available to Aid Pre-surgical Evaluation of Women for Ovarian Cancer
| - | FDA-cleared test helps direct women to the most appropriate surgeon, promoting better outcomes |
| - | Company also ranked among top 100 Best Corporate Citizens by Corporate Responsibility Magazine |
Quest Diagnostics Unveils Care360™ EHR
| - | Company Empowers Physicians to Embrace Digital Healthcare, Connect with Peers, and Work Toward Meaningful Use One Step at a Time |
| - | 90-Day Free Trial for Web-based Care360 EHR and Care360 ePrescribing Introduced at HIMSS10 |
| - | Fourth quarter diluted EPS grew 11% on revenue growth of 2.7%; cash from operations totaled $360 million |
| - | Full year diluted EPS grew 20% on revenue growth of 2.8%; cash from operations totaled $1 billion |
| - | 2010 EPS expected to be between $4.10 and $4.30 per diluted share |
| - | Listen to a replay of Quest Diagnostics' Fourth Quarter Conference Call |
| - | Read a Transcript of Company Prepared Comments |
Quest Diagnostics Increases Share Repurchase Authority By $750 Million